Therapeutic resistance remains a major barrier to durable cancer control despite advances in immunotherapy, targeted therapy, cellular therapies, chemotherapy, and radiotherapy. Although tumor cell-intrinsic genetic and epigenetic alterations are well-established drivers of resistance, treatment outcomes are also shape...
Yan-Jun Li, Su-Ling Xu, Huang-Ze Xie et al.· Drug resistance updates· 0 citations
Overall, this review establishes endothelial reprogramming as a central strategy for overcoming vascular immune gatekeeping and provides a mechanistic framework for biomarker-guided vascular-immune combination therapies in solid tumors.
Tian-Ming Zhang, C. Zhang, Chao Wang et al.· Cancer Letters· 0 citations
Immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) axis have transformed cancer therapy, yet reliable biomarkers for accurately predicting therapeutic benefit remain limited. Peripheral blood biomarkers have emerged as attractive candidates because of...
Xue-Jun Guo, Yan-Hui Wei, Zhao-Xu Miao et al.· Frontiers in Immunology· 1 citation
A context-dependent framework integrating macrophage heterogeneity, immunometabolism, spatial biology, biomarker development, and therapeutic decision-making to advance precision immunotherapy is proposed.
Xue-Jun Guo, Jing-Ya Yu, Xiao-Yan Lin et al.· Critical reviews in oncology...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.